| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/10-1/50 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/500-1/5000 | Human,Mouse,Rat |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human IL23R |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇与IL23R抗体相关的文献及其摘要概括：
1. **文献名称**：*"Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease"*
**作者**：William J. Sandborn等
**摘要**：该研究评估了抗IL-12/IL-23 p40单抗(乌司奴单抗)在中重度克罗恩病患者中的疗效。结果显示，乌司奴单抗在诱导和维持疾病缓解方面显著优于安慰剂，且安全性良好。
2. **文献名称**：*"Guselkumab, an anti-IL-23 monoclonal antibody, for the treatment of moderate-to-severe plaque psoriasis: Efficacy and safety analyses from a Phase III trial"*
**作者**：Kenneth B. Gordon等
**摘要**：古塞库单抗(靶向IL-23 p19亚基)在银屑病III期临床试验中显著改善患者皮损和症状，耐受性良好，证实IL-23特异性抗体在自身免疫疾病中的治疗潜力。
3. **文献名称**：*"The IL-23/Th17 axis in the immunopathogenesis of psoriasis"*
**作者**：Frank O. Nestle等
**摘要**：该综述总结了IL-23通过激活Th17细胞驱动银屑病炎症的机制，并讨论了靶向IL-23受体抗体(如利生奇珠单抗)在阻断致病通路中的关键作用。
4. **文献名称**：*"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis: A phase 3 randomised trial"*
**作者**：Andrew Blauvelt等
**摘要**：III期试验显示，抗IL-23 p19单抗替拉珠单抗较安慰剂或依那西普显著提高中重度银屑病患者皮损清除率，支持IL-23R靶向治疗的有效性和安全性。
以上文献均聚焦于IL-23受体抗体的作用机制、临床疗效及在免疫性疾病中的应用。
The IL-23 receptor (IL23R) is a key component of the IL-23 signaling pathway, which plays a pivotal role in mediating inflammatory and autoimmune responses. IL-23. a cytokine belonging to the IL-12 family, binds to IL23R—a heterodimeric receptor complex composed of IL23R and IL-12Rβ1 subunits. This interaction activates the JAK-STAT pathway, particularly STAT3. driving the differentiation and maintenance of Th17 cells, which produce pro-inflammatory cytokines like IL-17 and IL-22. Dysregulation of this pathway is implicated in chronic inflammatory diseases, including psoriasis, inflammatory bowel disease (IBD), and ankylosing spondylitis.
IL23R-targeted antibodies are biologic therapies designed to disrupt IL-23 signaling, thereby reducing pathogenic inflammation. These monoclonal antibodies either bind directly to the IL-23p19 subunit (e.g., risankizumab, guselkumab) or block IL-23’s interaction with its receptor (e.g., tildrakizumab). By selectively inhibiting IL-23. these agents suppress Th17 cell activation and downstream cytokine production without broadly impairing immune function. Clinical trials have demonstrated their efficacy in inducing and sustaining remission in conditions like moderate-to-severe plaque psoriasis and Crohn’s disease, often with favorable safety profiles compared to older biologics. Research continues to explore their potential in other IL-23/Th17-driven disorders, highlighting IL23R as a critical therapeutic target in precision immunology.
×
